Clinical trials: Chemotherapy-Related Nausea and/or Vomiting
Breast Cancer
Individualised Versus Standard Care for Breast Cancer Patients at High-risk for Chemotherapy-induced Nausea and Vomiting The ILIAD Study
The purpose of this study is to evaluate whether adding olanzapine 5mg to standard antiemetic medication can significantly reduce chemotherapy-induced nausea and vomiting in breast cancer patients receiving emetogenic…
- Trial name
- NCT02861859
- Testing
- Olanzapine
- Where
- Canada
- Volunteers
- 221 people
- Sponsor
- Ottawa Hospital Research Institute
Liver Cancer, Liver Metastasis
Effects of Acupoint Electro-stimulation on Preventing Nausea and Vomiting Induced by Cisplatin or Oxaliplatin
Objectives: This protocol is part of a larger grant funded by the NCI to create an international research center to study Traditional Chinese Medicine (TCM).
- Trial name
- NCT00430313
- Testing
- Electro-Stimulation of Yongquan (K1) Acupoint
- Sponsor
- M.D. Anderson Cancer Center
Chemotherapy Induced Nausea and Vomiting
Olanzapine Versus Placebo for Moderately Emetogenic Chemotherapy
A study comparing efficacy of olanzapine versus placebo to prevent nausea and vomiting from moderate emetic risk chemotherapy
- Trial name
- NCT06850454
- Testing
- olanzapine
- Where
- Thailand
- Volunteers
- 140 people
- Sponsor
- Mahidol University
Chemotherapy Induced Nausea and Vomiting
Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis (0000-041)
The purpose of this study is to assess whether timely feedback to providers on patient experiences with delayed chemotherapy induced nausea and vomiting (CINV) lead to differences in patient outcomes for subsequent cycles.
- Trial name
- C-PHONE (NCT00211601)
- Testing
- Disease Management Assessment
- Volunteers
- 1,500 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-induced Nausea and Vomiting
Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)
The purpose of this study is to evaluate the safety and tolerability of a 3-day intravenous (IV) fosaprepitant dimeglumine (MK-0517) regimen for the prevention of CINV in pediatric participants scheduled to receive emetogenic…
- Trial name
- NCT04054193
- Testing
- Fosaprepitant Dimeglumine, 5-HT3 antagonist, Dexamethasone
- Where
- 26 sites in United States, Greece and 7 more
- Volunteers
- 103 people
- Sponsor
- Merck Sharp & Dohme LLC
Gynecologic Cancer
Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients
The objective of this study is to investigate the efficacy of olanzapine as compared to neurokinin-1 receptor antagonists (NK1-RAs) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic…
- Trial name
- NCT04503668
- Testing
- Ondansetron, Dexamethasone, Neurokinin-1 Receptor Antagonist (NK1-RA)
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of Michigan Rogel Cancer Center
Chemotherapy Induced Nausea and Vomiting, Quality of Life (QOL)
Vomiting Prevention in Children With Cancer
The goal of this single arm trial is to learn if a machine learning (ML) model predicting the risk of vomiting within the next 96 hours will impact vomiting outcomes in inpatient cancer pediatric patients.
- Conditions
- Chemotherapy Induced Nausea and Vomiting, Quality of Life (QOL), Pediatric Cancer
- Trial name
- NCT06886451
- Testing
- ML-based intervention
- Where
- Canada
- Volunteers
- 1,953 people
- Sponsor
- The Hospital for Sick Children
Chemotherapy-Induced Nausea and Vomiting
Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)
The study will test aprepitant for the prevention of CINV in patients receiving their initial cycle of Moderately Emetogenic Chemotherapy (MEC).
- Trial name
- NCT00337727
- Testing
- aprepitant, Comparator: ondansetron, Comparator: dexamethasone
- Volunteers
- 848 people
- Sponsor
- Merck Sharp & Dohme LLC
Cancer, Tumors
Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and Dexamethasone
The purpose of this study is to compare the anti-emetic effect of ramosetron plus aprepitant and dexamethasone with palonosetron plus aprepitant and dexamethasone in patients receiving highly emetogenic chemotherapy.
- Trial name
- RAPA (NCT02532634)
- Testing
- ramosetron, aprepitant, dexamethasone, palonosetron, aprepitant, dexamethasone
- Where
- 10 sites in South Korea
- Volunteers
- 292 people
- Sponsor
- Kangdong Sacred Heart Hospital
Chemotherapy-induced Nausea and Vomiting
Effect of Foot Reflexology On Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients
This study aims to evaluate the effect of foot reflexology on chemotherapy-induced nausea and vomiting in breast cancer patients.
- Trial name
- NCT07322393
- Testing
- Foot Reflexology
- Volunteers
- 50 people
- Sponsor
- University of Health Sciences Lahore
Complications of Bone Marrow Transplant, Hematologic Neoplasms
Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens
The objective of this study is to compare the effectiveness of olanzapine added to standard triplet therapy (fosaprepitant, ondansetron, and dexamethasone) versus triplet therapy alone in preventing chemotherapy-induced nausea…
- Trial name
- FOND-O (NCT02635984)
- Testing
- Olanzapine
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- Augusta University
Pediatric Solid Tumor, Unspecified, Protocol Specific
Ondansetron (ODF) Versus Ondansetron Intravenously for the Prevention of Chemotherapy-induced Nausea and Vomiting Compare in Children
The purpose is to evaluate the efficacy of ondansetron oral soluble film plus dexamethasone in preventing chemotherapy-induced nausea and vomiting (CINV) with MEC/HEC chemotherapy in children with solid tumor.
- Trial name
- NCT06208917
- Testing
- Ondansetron (Oral soluble film OR injections) ,Dexamethasone
- Where
- China
- Volunteers
- 376 people
- Sponsor
- Yizhuo Zhang
Chemotherapy-Induced Nausea and Vomiting (CINV)
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)
This study aims to demonstrate that, when given concomitantly with a 5-hydroxytryptamine 3 (5-HT3) antagonist and a corticosteroid, a single 150 mg intravenous (IV) dose of fosaprepitant given on Day 1 is superior to the control…
- Trial name
- NCT01594749
- Testing
- Fosaprepitant dimeglumine, Dexamethasone, Ondansetron
- Volunteers
- 1,015 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-induced Nausea and Vomiting (CINV)
Granisetron Transdermal Patch for Prophylaxis of Delayed CINV
Transdermal granisetron has been shown to as effective as oral/ intravenous granisetron when administered with or without dexamethasone.
- Trial name
- NCT04912271
- Testing
- Granisetron transdermal patch, Palonosetron, Aprepitant
- Volunteers
- 140 people
- Sponsor
- Fudan University
Male Breast Cancer, Nausea and Vomiting
Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer
RATIONALE: Antiemetic drugs, such as dexamethasone, ondansetron hydrochloride, and palonosetron hydrochloride, may help lessen or prevent nausea and vomiting caused by chemotherapy.
- Conditions
- Male Breast Cancer, Nausea and Vomiting, Stage I Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT00343863
- Testing
- palonosetron hydrochloride, cyclophosphamide, dexamethasone
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Washington
Colon Cancer
Phamacokinetic and Pharmacodynamic Study of Ramosetron in Chemotherapy Induced Nasea and Vomiting
This study is designted to know optimal dose of Ramosteron to control for chemotherapy induced nasea and vomoting (CINV)based on its pharmacokinetics, pharmacodynamic study and clinilcal parameters using Rhodes Index.
- Trial name
- NCT02076529
- Testing
- Ramosetron 0.3mg, Ramosetron 0.45mg, Ramosetron 0.6mg
- Where
- South Korea
- Volunteers
- 51 people
- Sponsor
- Chonnam National University Hospital
Cervical Cancer, Nasopharyngeal Cancer
Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer
The study is to evaluate the antiemetic effect of adding fosaprepitant to biplet regimen of tropisetron and dexamethasone for patients with cervical cancer or nasopharyngeal cancer treated with radiotherapy and concomitant weekly…
- Conditions
- Cervical Cancer, Nasopharyngeal Cancer, Chemotherapy-induced Nausea and Vomiting, Radiation-Induced Nausea and Vomiting
- Trial name
- NCT05564286
- Testing
- Fosaprepitant, tropisetron, Dexamethasone
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Shantou University Medical College
Neoplasms, Child
VR to Improve CINV, Sleep and Pain Among Children With Cancer in HK
Chemotherapy-induced nausea and vomiting, sleep quality and pain are the common symptoms experienced by children with cancer. These symptoms significantly devastate the children's quality of life.
- Conditions
- Neoplasms, Child, Nausea, Vomiting
- Trial name
- NCT04853303
- Testing
- Hypnosis VR
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- The Hong Kong Polytechnic University
Chemotherapy-induced Nausea and Vomiting, Adverse Event
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin
This is a multicentre, single-arm, phase II study to investigate the safety and antiemetic efficacy of Akynzeo (a fixed dose combination of palonosetron and netupitant) plus dexamethasone in patients receiving concomitant…
- Conditions
- Chemotherapy-induced Nausea and Vomiting, Adverse Event, Cervical Cancer
- Trial name
- NCT03668639
- Testing
- Akynzeo, Dexamethasone
- Where
- Denmark
- Volunteers
- 80 people
- Sponsor
- Christina Ruhlmann
Chemotherapy-Related Nausea and/or Vomiting, Early Stage Breast Carcinoma
Evaluating the Association Among Changes in Gut Microbiome, Fatigue, and Chemotherapy-Induced Nausea in Early Stage Breast Cancer
This pilot study seeks to understand how changes in the bacteria composition (microbiome) of the gut may be associated with the occurrence of fatigue and chemotherapy-induced nausea (CIN) in women undergoing chemotherapy for…
- Conditions
- Chemotherapy-Related Nausea and/or Vomiting, Early Stage Breast Carcinoma, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT05417867
- Testing
- Biospecimen Collection, Questionnaire Administration
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- Mayo Clinic